Cancer NetworkOriginal article
<![CDATA[Early Camizestrant Is Favored Upon ESR1 Mutation Emergence in Breast Cancer]]>
Conferencecamizestrantoral SERDsPositive
AI Analysis
Summary
Dr. Erica L. Mayer discusses clinical strategy recommendations for camizestrant use in breast cancer patients with ESR1 mutations, suggesting early switching rather than reserving oral SERDs for later progression.
Importance:4/10
Sentiment:
0.50
breast cancerESR1 mutationSERDtreatment strategyclinical opinion
Read the original article
Published by Cancer Network on September 10, 2026 8:00 PM